Date: 2016-07-12 04:22:18Medicine Clinical medicine Cancer treatments Immunology Oncology Immunotherapy Virotherapy Glioblastoma Chemotherapy Immune system Cancer immunotherapy ALECSAT | | VAXIMM initiates Phase 1 translational study in glioblastoma with oral T-cell immunotherapy, VXM01 Basel (Switzerland) and Mannheim (Germany), July 12, 2016 – VAXIMM AG, a Swiss/German biotech company focused on develoAdd to Reading ListSource URL: sunstone.euDownload Document from Source Website File Size: 362,33 KBShare Document on Facebook
|